ArticleScientific reports2025
Characterization of carbapenem-resistant biofilm forming Acinetobacter baumannii isolates from clinical and surveillance samples.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed.
- Should I stay or should I go? DNA damage thresholds drive stay-or-go decisions inJournal of bacteriology · 2026Review
- Review
- Daily rhythms modulate Acinetobacter baumannii physiology impacting infection outcome and antibiotic-inactivating capacity.Scientific reports · 2026Article
- Genomic and phenotypic analysis of multidrug-resistant Acinetobacter baumannii focusing on efflux pump activity and biofilm-associated genes.Molecular biology reports · 2026Article
- Harnessing the power of ferulic acid as a dual-action strategy against biofilm-forming extensively drug-resistant Acinetobacter baumannii isolated from cancer patients: in vitro and in vivo study.BMC microbiology · 2026Article
- Draft genome sequence of an Acinetobacter baumannii strain belonging to CC79 isolated from a reference hospital in Brazil.Molecular biology reports · 2026Article
- Carbapenem resistance genes and biofilm-virulence uncoupling inFrontiers in antibiotics · 2026Article
- Carbapenem-resistant Acinetobacter baumannii bloodstream infections and specific phages isolation, analysis and application.Frontiers in cellular and infection microbiology · 2026Article
- Impact of Incremental Antiseptic Selection on Antibiotic Cross-Resistance and Enhanced Biofilm Formation inInternational journal of microbiology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Acinetobacter baumannii (A. baumannii) is an important nosocomial pathogen responsible for a wide range of human infections. The emergence of multidrug resistance (MDR) causes life-threatening nosocomial infections. Also, the formation of biofilm helps it survive on abiotic surfaces and is transferred through healthcare workers, thereby causing nosocomial infections. Hence, we study the current antibiotic resistance patterns and virulence factors in our clinical and colonizing isolates. A total of 92 isolates (44 colonizing and 48 clinical) of A. baumannii were included in the study. Antibiotic susceptibility testing was performed by VITEK 2. Biofilm formation was assessed by the tissue culture plate method. Polymerase chain reaction (PCR) for oxacillinases, MBLs and biofilm-associated genes were performed. Meropenem resistance was found in 42 (87.5%) of the clinical and 44 (97.7%) of the colonizing isolates. A strongly adherent biofilm was produced by 11 (22.91%) of the clinical and 12 (27.27%) of the colonizing isolates. Biofilm-associated genes, ompA, bap and csuE were present in 45 (93.7%), 47 (97.9%) and 44 (91.6%) of the clinical isolates, respectively and in all the colonizing isolates. bla
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.